The current epidemic situation of coronavirus disease 2019 (COVID-19) still remained severe. As the National Clinical Research Center for Infectious Diseases, the First Affiliated Hospital of Zhejiang University School of Medicine is the primary medical care center for COVID-19 in Zhejiang province. Based on the present expert consensus carried out by National Health Commission and National Administration of Traditional Chinese Medicine, our team summarized and established an effective treatment strategy centered on “Four-Anti and Two-Balance” for clinical practice.
The “Four-Anti and Two-Balance” strategy included antivirus, anti-shock, anti-hyoxemia, anti-secondary infection, and maintaining of water, electrolyte and acid base balance and microecological balance. Meanwhile, integrated multidisciplinary personalized treatment was recommended to improve therapeutic effect. The importance of early viralogical detection, dynamic monitoring of inflammatory indexes and chest radiograph was emphasized in clinical decision-making.
Sputum was observed with the highest positive rate of RT-PCR results. Viral nucleic acids could be detected in 10%patients’ blood samples at acute period and 50%of patients had positive RT-PCR results in their feces. We also isolated alive viral strains from feces, indicating potential infectiousness of feces.Dynamic cytokine detection was necessary to timely identifying cytokine storms and application of artificial liver blood purification system.
FcRn, His-Tag |
71285-1 |
BPS Bioscience |
100 µg |
EUR 345 |
Description: Human FcRn, also known as Neonatal Fc receptor, GenBank Accession number NM_001136019, a.a. 212-1313 with C-terminalHis-Tag. MW = 32 kDa, expressed in an HEK293 expression system. |
FcRn, His-Tag |
71285-2 |
BPS Bioscience |
1 mg |
EUR 2940 |
Description: Human FcRn, also known as Neonatal Fc receptor, GenBank Accession number NM_001136019, a.a. 212-1313 with C-terminalHis-Tag. MW = 32 kDa, expressed in an HEK293 expression system. |
FcRn Blocking Peptide |
MBS9621312-1mg |
MyBiosource |
1mg |
EUR 380 |
FcRn Blocking Peptide |
MBS9621312-5x1mg |
MyBiosource |
5x1mg |
EUR 1650 |
FcRn-Specific Antibody |
abx233063-100g |
Abbexa |
100 µg |
EUR 350 |
FcRn-Specific Antibody |
abx233063-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
FcRn-Specific antibody |
E39-03063 |
EnoGene |
100ug/100ul |
EUR 225 |
Description: Available in various conjugation types. |
FcRn-Specific Antibody |
MBS9611359-01mL |
MyBiosource |
0.1mL |
EUR 260 |
FcRn-Specific Antibody |
MBS9611359-02mL |
MyBiosource |
0.2mL |
EUR 305 |
FcRn-Specific Antibody |
MBS9611359-5x02mL |
MyBiosource |
5x0.2mL |
EUR 1220 |
human FcRn, His tag |
E410A15-10 |
EnoGene |
10μg |
EUR 495 |
human FcRn,His tag |
E4A10L01 |
EnoGene |
50ug |
EUR 255 |
Description: Available in various conjugation types. |
Human FcRn, His tag |
MBS8575042-001mg |
MyBiosource |
0.01mg |
EUR 575 |
Human FcRn, His tag |
MBS8575042-5x001mg |
MyBiosource |
5x0.01mg |
EUR 2440 |
Mouse FcRn ELISA Kit |
MBS8248436-5x96Tests |
MyBiosource |
5x96Tests |
EUR 2880 |
Mouse FcRn ELISA Kit |
MBS8248436-96Tests |
MyBiosource |
96Tests |
EUR 645 |
FCGRT/FCRN Rabbit mAb |
A23161 |
Abclonal |
100μL |
EUR 1657.89 |
|
Description: A synthetic peptide corresponding to a sequence within amino acids 700-800 of human VAV3 (Q9UKW4). |
FcRn (FCGRT/B2M) Blocker |
101468-1 |
BPS Bioscience |
50 µg |
EUR 355 |
Description: The FcRn (FCGRT/B2M) blocker (Fc-Tag) is a purified human protein corresponding to the Fc region of an antibody which has been engineered to bind to human neonatal Fc Receptor for IgG (FcRn; FCGRT/B2M) with high affinity. This antibody has been tested for specific binding to human FcRn (BPS Bioscience #71283) and it blocks the binding of FcRn with immunoglobulins G. |
FcRn (FCGRT/B2M) Blocker |
101468-2 |
BPS Bioscience |
100 µg |
EUR 510 |
Description: The FcRn (FCGRT/B2M) blocker (Fc-Tag) is a purified human protein corresponding to the Fc region of an antibody which has been engineered to bind to human neonatal Fc Receptor for IgG (FcRn; FCGRT/B2M) with high affinity. This antibody has been tested for specific binding to human FcRn (BPS Bioscience #71283) and it blocks the binding of FcRn with immunoglobulins G. |
FCGRT/FcRn (IgG Transporter) |
MBS4380899-002mgWithBSAAzideat02mgmL |
MyBiosource |
0.02mg(WithBSA&Azideat0.2mg/mL) |
EUR 230 |
FCGRT/FcRn (IgG Transporter) |
MBS4380899-01mgWithBSAAzideat02mgmL |
MyBiosource |
0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 405 |
FCGRT/FcRn (IgG Transporter) |
MBS4380899-01mgWithoutBSAAzideat1mgmL |
MyBiosource |
0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 405 |
FCGRT/FcRn (IgG Transporter) |
MBS4380899-5x01mgWithBSAAzideat02mgmL |
MyBiosource |
5x0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 1725 |
FCGRT/FcRn (IgG Transporter) |
MBS4380899-5x01mgWithoutBSAAzideat1mgmL |
MyBiosource |
5x0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 1725 |
anti- FcRn-Specific antibody |
FNab03063 |
FN Test |
100µg |
EUR 702 |
|
Description: Antibody raised against FcRn-Specific |
Recombinant Human FcRn Protein |
RP01037 |
Abclonal |
5 μg |
EUR 297.57 |
|
Recombinant Mouse FcRn Protein |
RP02030 |
Abclonal |
500μg |
EUR 258.6 |
|
FcRn-Specific Blocking Peptide |
DF12607-BP |
Affbiotech |
1mg |
EUR 234 |
Recombinant Cynomolgus FcRn Protein |
RP02363 |
Abclonal |
500μg |
EUR 258.6 |
|
Mouse FCRN/FCGRT ELISA Kit |
EK5682 |
SAB |
96 tests |
EUR 599 |
|
Rabbit Anti-Human FcRn/b2M Protein (FCGRT/FcRn 1-297aa+B2M 1-119aa heterodimer) IgG, Aff pure |
FCRN11-A |
Alpha Diagnostics |
100 ug |
EUR 416.4 |
FCGRT/FCRN Recombinant Rabbit mAb |
BS49115 |
Bioworld Biotech |
50 ul |
EUR 398 |
|
Description: Store at -20°C. Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt. |
Human FcRn (FCGRT & B2M), His Tag |
E24PHA115 |
EnoGene |
50 μg |
EUR 262 |
FcRn & B2M Heterodimer Recombinant Protein |
92-311 |
ProSci |
0.05 mg |
EUR 651.3 |
Description: FcRn complex consist of two subunits: IgG receptor FcRn large subunit p51(alpha chain) and Beta-2-microglobulin(Beta chain). The complexes is similar in structure to MHC class I-like heterodimer. Beta-2-microglobulin involved in the presentation of peptide antigens to the immune system. FcRn binds to the Fc region of monomeric immunoglobulins gamma, mediates the uptake of IgG from milk,Possible role in transfer of immunoglobulin G from mother to fetus. A principal component of antibody transport is the neonatal receptor for the Fc portion of immunoglobulin, a heterodimer of a MHC-1 alpha-chain homolog ( FcRn ) and beta-2-microglobulin ( B2M ). |
FcRn & B2M Heterodimer Recombinant Protein |
92-590 |
ProSci |
0.05 mg |
EUR 481.2 |
Description: FcRn complex consist of two subunits: IgG receptor FcRn large subunit p51(alpha chain) and Beta-2-microglobulin(Beta chain). The complexes is similar in structure to MHC class I-like heterodimer. Beta-2-microglobulin involved in the presentation of peptide antigens to the immune system. FcRn binds to the Fc region of monomeric immunoglobulins gamma, mediates the uptake of IgG from milk,Possible role in transfer of immunoglobulin G from mother to fetus. A principal component of antibody transport is the neonatal receptor for the Fc portion of immunoglobulin, a heterodimer of a MHC-1 alpha-chain homolog ( FcRn ) and beta-2-microglobulin ( B2M ). |
Human FcRn&b2M HEK293 Cell Line |
E24C00187 |
EnoGene |
each |
EUR 1225 |
Description: Human |
Recombinant Human FcRn Heterodimer Protein |
RP02365 |
Abclonal |
100μg |
EUR 283.4 |
Human IgG receptor FcRn Rabbit mAb |
E2R50150 |
EnoGene |
100ul |
EUR 385 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
IgG receptor FcRn large subunit p51 |
AP83191 |
SAB |
1mg |
EUR 2640 |
|
IgG receptor FcRn large subunit p51 |
AP83431 |
SAB |
1mg |
EUR 2640 |
|
Mouse FCRN/FCGRT PicoKine ELISA Kit |
MBS178527-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3935 |
Mouse FCRN/FCGRT PicoKine ELISA Kit |
MBS178527-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 855 |
IgG receptor FcRn large subunit p51 |
MBS7042739-002mg |
MyBiosource |
0.02mg |
EUR 1660 |
IgG receptor FcRn large subunit p51 |
MBS7042739-01mg |
MyBiosource |
0.1mg |
EUR 2615 |
IgG receptor FcRn large subunit p51 |
MBS7042739-5x01mg |
MyBiosource |
5x0.1mg |
EUR 11730 |
Biotinylated Recombinant Cynomolgus FcRn Protein |
RP02364 |
Abclonal |
500μg |
EUR 421.56 |
|
Anti-Human FCGRT/FCRN Antibody (SAA0135) |
MBS1564415-01mg |
MyBiosource |
0.1mg |
EUR 405 |
Anti-Human FCGRT/FCRN Antibody (SAA0135) |
MBS1564415-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1520 |
Anti-Human FCGRT/FCRN Antibody (SAA0136) |
MBS1564416-01mg |
MyBiosource |
0.1mg |
EUR 405 |
Anti-Human FCGRT/FCRN Antibody (SAA0136) |
MBS1564416-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1520 |
FCGRT/FCRN (16A10) Rabbit Monoclonal Antibody |
E28M2155 |
EnoGene |
100ul |
EUR 295 |
Mouse FCRN/FCGRT ELISA Kit PicoKine® |
EK1454 |
BosterBio |
96 wells |
EUR 750 |
|
Description: Mouse FCRN/FCGRT ELISA Kit PicoKine® (96 Tests). Quantitate Mouse Fcgrt in cell culture supernatants, serum, plasma (heparin, EDTA) and cell lysates. Sensitivity: 10pg/ml. |
Recombinant (HEK) Human FcRn/b2M Protein (FCGRT/FcRn 1-297aa+B2M 1-119aa heterodimer protein, >95%, his-tag, ~44 kda, low endotoxins) |
FCRN15-R-25 |
Alpha Diagnostics |
25 ug |
EUR 416.4 |
Recombinant (HEK) Mouse FcRn/b2M Protein (FCGRT/FcRn 1-297aa+B2M 1-119aa heterodimer protein, >95%, his-tag, ~44 kda, low endotoxins) |
FCRN16-R-25 |
Alpha Diagnostics |
25 ug |
EUR 416.4 |
Mouse Neonatal Fc Receptor (FcRn) ELISA Kit |
IMSFCRNKT |
Innovative research |
each |
EUR 890 |
|
Description: Mouse Neonatal Fc Receptor (FcRn) ELISA Kit |
Mouse Neonatal Fc Receptor (FcRn) ELISA Kit |
MBS8420553-1Kit |
MyBiosource |
1Kit |
EUR 755 |
Mouse Neonatal Fc Receptor (FcRn) ELISA Kit |
MBS8420553-5x1Kit |
MyBiosource |
5x1Kit |
EUR 3455 |
Recombinant mouse FcRn Protein, Avi & His Tag |
E40KMP1751 |
EnoGene |
20ug |
EUR 495 |
Recombinant mouse FcRn Protein, Avi His Tag |
E40KMP2167 |
EnoGene |
20ug |
EUR 495 |
Recombinant Human FcRn protein, C-His Tag |
MBS1560770-005mg |
MyBiosource |
0.05mg |
EUR 345 |
Recombinant Human FcRn protein, C-His Tag |
MBS1560770-01mg |
MyBiosource |
0.1mg |
EUR 450 |
Recombinant Human FcRn protein, C-His Tag |
MBS1560770-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1710 |
Recombinant Human FcRn/FCGRT Protein, His Tag |
E40KMH1078 |
EnoGene |
20ug |
EUR 495 |
Recombinant Mouse FcRn/Fcgrt Protein, His Tag |
E40MOP2152 |
EnoGene |
20ug |
EUR 495 |
FcRn (FCGRT/B2M), His-Tag (Mouse) HiP™ |
11349 |
BPS Bioscience |
100 µg |
EUR 320 |
Description: Mouse FcRn also known as Neonatal Fc receptor is a heterodimer of FCGRT (Fc Fragment of IgG Receptor and Transporter) and B2M (beta 2 microglobulin), GenBank Accession numbers NM_010189 and NM_009735; a.a. 22-297 and a.a. 1-119 respectively. FCGRT has a C-terminal His-Avi-tag. These proteins are co-expressed in a HEK293 expression system. FcRn MW = 34 kDa. B2M MW=14 kDa. |
Recombinant Mouse FcRn & B2M Heterodimer (C-6His) |
CK96-10ug |
Novoprotein |
10ug |
EUR 151.2 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
Recombinant Mouse FcRn & B2M Heterodimer (C-6His) |
CK96-1mg |
Novoprotein |
1mg |
EUR 2252.4 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
Recombinant Mouse FcRn & B2M Heterodimer (C-6His) |
CK96-500ug |
Novoprotein |
500ug |
EUR 1593.6 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
Recombinant Mouse FcRn & B2M Heterodimer (C-6His) |
CK96-50ug |
Novoprotein |
50ug |
EUR 278.4 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
Recombinant Human FcRn & B2M Heterodimer (C-6His) |
CI01-10ug |
Novoprotein |
10ug |
EUR 187.2 |
Description: Lyophilized from a 0.2 μm filtered solution of 50mM HEPES,150mM Nacl,pH7.4. |
Recombinant Human FcRn & B2M Heterodimer (C-6His) |
CI01-1mg |
Novoprotein |
1mg |
EUR 2739.6 |
Description: Lyophilized from a 0.2 μm filtered solution of 50mM HEPES,150mM Nacl,pH7.4. |
Recombinant Human FcRn & B2M Heterodimer (C-6His) |
CI01-500ug |
Novoprotein |
500ug |
EUR 1935.6 |
Description: Lyophilized from a 0.2 μm filtered solution of 50mM HEPES,150mM Nacl,pH7.4. |
Recombinant Human FcRn & B2M Heterodimer (C-6His) |
CI01-50ug |
Novoprotein |
50ug |
EUR 442.8 |
Description: Lyophilized from a 0.2 μm filtered solution of 50mM HEPES,150mM Nacl,pH7.4. |
Recombinant Human FcRn & B2M Heterodimer (C-6His) |
AP75984 |
SAB |
1mg |
EUR 3209 |
|
Recombinant Mouse FcRn & B2M Heterodimer (C-6His) |
AP76211 |
SAB |
1mg |
EUR 2649 |
|
Recombinant Cynomolgus FcRn Protein, Avi His Tag |
E40KMP1971 |
EnoGene |
20ug |
EUR 495 |
FCGRT / FcRn (IgG Transporter)(FCGRT/2932), 1mg/mL |
BNUM2932-50 |
Biotium |
1uL |
EUR 396 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FCGRT / FcRn (IgG Transporter)(FCGRT/2932), 0.2mg/mL |
BNUB2932-100 |
Biotium |
1uL |
EUR 225 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FCGRT / FcRn (IgG Transporter)(FCGRT/2932), 0.2mg/mL |
BNUB2932-500 |
Biotium |
1uL |
EUR 485 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
FCGRT/FCRN Rabbit anti-Human Polyclonal Antibody |
MBS2402875-005mL |
MyBiosource |
0.05mL |
EUR 615 |
FCGRT/FCRN Rabbit anti-Human Polyclonal Antibody |
MBS2402875-5x005mL |
MyBiosource |
5x0.05mL |
EUR 2605 |
FCGRT/FCRN Rabbit anti-Human Polyclonal Antibody |
MBS2403049-005mL |
MyBiosource |
0.05mL |
EUR 615 |
FCGRT/FCRN Rabbit anti-Human Polyclonal Antibody |
MBS2403049-5x005mL |
MyBiosource |
5x0.05mL |
EUR 2605 |
Recombinant Mouse FcRn/FCGRT & B2M Heterodimer Protein |
RP00694 |
Abclonal |
50μg |
EUR 41.8 |
Human IgG receptor FcRn large subunit p51 (FCGRT) |
1-CSB-EP008545HU |
Cusabio |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10ug
- 50ug
- 100ug
- 200ug
- 500ug
- 1MG
|
|
Description: Recombinant Human IgG receptor FcRn large subunit p51(FCGRT),partial expressed in E.coli |
Human IgG receptor FcRn large subunit p51 (FCGRT) |
1-CSB-MP008545HU |
Cusabio |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
Description: Recombinant Human IgG receptor FcRn large subunit p51(FCGRT),partial expressed in Mammalian cell |
Human IgG receptor FcRn large subunit p51 (FCGRT) |
1-CSB-YP008545HU |
Cusabio |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10ug
- 50ug
- 100ug
- 200ug
- 500ug
- 1MG
|
|
Description: Recombinant Human IgG receptor FcRn large subunit p51(FCGRT),partial expressed in Yeast |
Cynomolgus / Rhesus Macaque FcRn (FCGRT & B2M), Fc Tag |
E24PCA041 |
EnoGene |
50 μg |
EUR 200 |
Cynomolgus / Rhesus Macaque FcRn (FCGRT & B2M), His Tag |
E24PCA042 |
EnoGene |
50 μg |
EUR 262 |
FCGRT, CT (FCGRT, FCRN, IgG receptor FcRn large subunit p51, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor) |
MBS6001682-02mL |
MyBiosource |
0.2(mL |
EUR 695 |
FCGRT, CT (FCGRT, FCRN, IgG receptor FcRn large subunit p51, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor) |
MBS6001682-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2975 |
HEK293/FcRn (FCGRT & B2M), GFP Tag Stable Cell Line |
CHEK-ATP132 |
ACROBIOSYSTEMS |
2Vials |
EUR 3858.6 |
|
Description: FCGRT & B2M heterodimer protein (FcRn complex) consist of two subunits: p51 (equivalent to FCGRT), and p14 (equivalent to beta-2-microglobulin), and forms an MHC class I-like heterodimer. Fc fragment of IgG, receptor, transporter, alpha (FCGRT) binds to the Fc region of monomeric immunoglobulins gamma and mediates the uptake of IgG from milk. FCGRT possible role in transfer of immunoglobulin G from mother to fetus. Beta-2-microglobulin (B2M) is a component of the class I major histocompatibility complex (MHC) and involved in the presentation of peptide antigens to the immune system. |
FCGRT, CT (FCGRT, FCRN, IgG receptor FcRn large subunit p51, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor) (AP) |
MBS6298670-02mL |
MyBiosource |
0.2mL |
EUR 980 |
FCGRT, CT (FCGRT, FCRN, IgG receptor FcRn large subunit p51, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor) (AP) |
MBS6298670-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
FCGRT, CT (FCGRT, FCRN, IgG receptor FcRn large subunit p51, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor) (APC) |
MBS6298671-02mL |
MyBiosource |
0.2mL |
EUR 980 |
FCGRT, CT (FCGRT, FCRN, IgG receptor FcRn large subunit p51, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor) (APC) |
MBS6298671-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
FCGRT, CT (FCGRT, FCRN, IgG receptor FcRn large subunit p51, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor) (PE) |
MBS6298680-02mL |
MyBiosource |
0.2mL |
EUR 980 |
FCGRT, CT (FCGRT, FCRN, IgG receptor FcRn large subunit p51, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor) (PE) |
MBS6298680-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
Recombinant Human IgG receptor FcRn large subunit p51 |
MBS9422292-002mg |
MyBiosource |
0.02mg |
EUR 320 |
Recombinant Human IgG receptor FcRn large subunit p51 |
MBS9422292-01mg |
MyBiosource |
0.1mg |
EUR 540 |
Recombinant Human IgG receptor FcRn large subunit p51 |
MBS9422292-1mg |
MyBiosource |
1mg |
EUR 2070 |
Recombinant Human IgG receptor FcRn large subunit p51 |
MBS9422292-5x1mg |
MyBiosource |
5x1mg |
EUR 9160 |
Recombinant Human IgG receptor FcRn large subunit p51 |
MBS9420235-002mg |
MyBiosource |
0.02mg |
EUR 285 |
Recombinant Human IgG receptor FcRn large subunit p51 |
MBS9420235-01mg |
MyBiosource |
0.1mg |
EUR 470 |
Recombinant Human IgG receptor FcRn large subunit p51 |
MBS9420235-1mg |
MyBiosource |
1mg |
EUR 1785 |
Recombinant Human IgG receptor FcRn large subunit p51 |
MBS9420235-5x1mg |
MyBiosource |
5x1mg |
EUR 7885 |
Recombinant Human FcRn & B2M Heterodimer Protein (His Tag) |
PKSH032422-10ug |
Elabscience Biotech |
10ug |
EUR 129 |
|
Description: Human |
Recombinant Human FcRn & B2M Heterodimer Protein (His Tag) |
PKSH032422-50ug |
Elabscience Biotech |
50ug |
EUR 375 |
|
Description: Human |
Recombinant Mouse FcRn & B2M Heterodimer Protein (His Tag) |
PKSM041017-10ug |
Elabscience Biotech |
10ug |
EUR 92 |
|
Description: Mouse |
Recombinant Mouse FcRn & B2M Heterodimer Protein (His Tag) |
PKSM041017-50ug |
Elabscience Biotech |
50ug |
EUR 214 |
|
Description: Mouse |
IgG receptor FcRn large subunit p51 Polyclonal Antibody |
42167 |
SAB |
100μg |
EUR 390 |
IgG receptor FcRn large subunit p51 Polyclonal Antibody |
42167-100ul |
SAB |
100ul |
EUR 399.6 |
Fc (IgG1): FcRn Inhibitor Screening Colorimetric Assay Kit |
78501 |
BPS Bioscience |
96 rxns. |
EUR 830 |
Description: The Fc (IgG1): FcRn Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling neutralizing antibodies or inhibitors of the interaction between Fc (IgG1) and human FcRn. _x000D_The assay requires only a few steps. First, Fc (IgG1) is coated on a 96-well plate overnight. After blocking, the protein is pre-incubated with the inhibitor or neutralizing antibody. Upon subsequent incubation with Biotin-FcRn, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which can be quenched and measured using a UV/Vis microplate reader. |
Recombinant Human FcRn & B2M Heterodimer Protein (C-6His) |
MBS2552658-001mg |
MyBiosource |
0.01mg |
EUR 180 |
Recombinant Human FcRn & B2M Heterodimer Protein (C-6His) |
MBS2552658-005mg |
MyBiosource |
0.05mg |
EUR 380 |
Recombinant Human FcRn & B2M Heterodimer Protein (C-6His) |
MBS2552658-5x005mg |
MyBiosource |
5x0.05mg |
EUR 1690 |
Recombinant Mouse FcRn & B2M Heterodimer Protein (C-6His) |
MBS2553494-001mg |
MyBiosource |
0.01mg |
EUR 155 |
Recombinant Mouse FcRn & B2M Heterodimer Protein (C-6His) |
MBS2553494-005mg |
MyBiosource |
0.05mg |
EUR 240 |
Recombinant Mouse FcRn & B2M Heterodimer Protein (C-6His) |
MBS2553494-5x005mg |
MyBiosource |
5x0.05mg |
EUR 1080 |
IgG receptor FcRn large subunit p51 Polyclonal Antibody |
MBS9415363-01mg |
MyBiosource |
0.1mg |
EUR 350 |
IgG receptor FcRn large subunit p51 Polyclonal Antibody |
MBS9415363-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1420 |
FCGRT, CT (FCGRT, FCRN, IgG receptor FcRn large subunit p51, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor) (Biotin) |
MBS6298672-02mL |
MyBiosource |
0.2mL |
EUR 980 |
FCGRT, CT (FCGRT, FCRN, IgG receptor FcRn large subunit p51, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor) (Biotin) |
MBS6298672-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
FCGRT, CT (FCGRT, FCRN, IgG receptor FcRn large subunit p51, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor) (FITC) |
MBS6298673-02mL |
MyBiosource |
0.2mL |
EUR 980 |
FCGRT, CT (FCGRT, FCRN, IgG receptor FcRn large subunit p51, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor) (FITC) |
MBS6298673-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
Rat IgG receptor FcRn large subunit p51 ELISA Kit |
MBS2884822-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 4630 |
Rat IgG receptor FcRn large subunit p51 ELISA Kit |
MBS2884822-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 440 |
Rat IgG receptor FcRn large subunit p51 ELISA Kit |
MBS2884822-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 2480 |
Rat IgG receptor FcRn large subunit p51 ELISA Kit |
MBS2884822-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 580 |
Mouse IgG receptor FcRn large subunit p51 ELISA Kit |
EK3291 |
SAB |
96 tests |
EUR 739 |
|
Human IgG receptor FcRn large subunit p51 ELISA Kit |
EK3292 |
SAB |
96 tests |
EUR 636 |
|
Human IgG receptor FcRn large subunit p51 ELISA Kit |
MBS2884293-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 4080 |
Human IgG receptor FcRn large subunit p51 ELISA Kit |
MBS2884293-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 390 |
Human IgG receptor FcRn large subunit p51 ELISA Kit |
MBS2884293-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 2220 |
Human IgG receptor FcRn large subunit p51 ELISA Kit |
MBS2884293-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 520 |
The “Four-Anti and Two-Balance” strategy effectively increased cure rate and reduced mortality. Early antiviral treatment could alleviate disease severity and prevent illness progression, and we found lopinavir/ritonavir combined with abidol showed antiviral effects in COVID-19. Shock and hypoxemia were usually caused by cytokine storms. The artificial liver blood purification system could rapidly remove inflammatory mediators and block cytokine storm.Moreover, it also favored the balance of fluid, electrolyte and acid-base and thus improved treatment efficacy in critical illness. For cases of severe illness, early and also short period of moderate glucocorticoid was supported. Patients with oxygenation index below 200 mmHg should be transferred to intensive medical center.
Conservative oxygen therapy was preferred and noninvasive ventilation was not recommended. Patients with mechanical ventilation should be strictly supervised with cluster ventilator-associated pneumonia prevention strategies. Antimicrobial prophylaxis was not recommended except for patients with long course of disease, repeated fever and elevated procalcitonin (PCT), meanwhile secondary fungal infection should be concerned.Some patients with COVID-19 showed intestinal microbial dysbiosis with decreased probiotics such as Lactobacillus and Bifidobacterium, so nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation. Anxiety and fear were common in patients with COVID-19.
Therefore,we established dynamic assessment and warning for psychological crisis. We also integrated Chinese medicine in treatment to promote disease rehabilitation through classification methods of traditional Chinese medicine. We optimized nursing process for severe patients to promote their rehabilitation. It remained unclear about viral clearance pattern after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Therefore, two weeks’ quarantine for discharged patients was required and a regular following up was also needed.The Zhejiang experience and suggestions have been implemented in our center and achieved good results. However, since COVID-19 was a newly emerging disease, more work was warranted to improve strategies of prevention, diagnosis and treatment for COVID-19.